New studies on retatrutides, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, demonstrate promising results in addressing obesity and type 2 diabetes. Early evidence from clinical experiments point to notable diminutions in body mass and improved glucose levels. Further e